Trial Profile
Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors (TALENT STUDY)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Appendiceal cancer; Colon cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms TALENT
- 23 Apr 2023 Results pooled analysis from SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT) published in the European Journal of Cancer
- 08 Jun 2021 Results of plasma biomarker study assessing proangiogenic profiling (n=85), presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 04 May 2021 Primary endpoint (ORR by central radiology assessment for the GI-NET cohort) has not been met , according to Results published in the Journal of Clinical Oncology